[Skip to Content]
[Skip to Content Landing]
Article
March 1969

Diphenidol and Vestibular Function: A Comparative Study With Chlorpromazine in Rabbits

Author Affiliations

Los Angeles

From the Department of Surgery, Division of Head and Neck Surgery, Otology Section, UCLA School of Medicine, and the Cedars-Sinai Medical Research Institute, Division of Otolaryngology, Cedars-Sinai Medical Center, Los Angeles.

Arch Otolaryngol. 1969;89(3):488-493. doi:10.1001/archotol.1969.00770020490009
Abstract

INCREASING interest has been displayed in the development of potent and specific antivertigo drugs which are relatively free of the side effects noted with many of the agents in use today.

Diphenidol (Vontrol) was introduced as an antivertigo, antiemetic agent which does not exhibit the side effects that may accompany antihistamines or phenothiazines.1 These effects include sedation, hypotension, and extrapyramidal signs. Chemically, diphenidol (Vontrol) is α, α-diphenyl-1-piperidinebutanol. Studies have suggested that this drug has its effect upon the central vestibular mechanism and the chemoreceptor trigger zone.1 Clinical evaluations of diphenidol indicate that it is an effective antiemetic, and can be useful in controlling labyrinthine vertigo.2 Cutt et al3 used diphenidol and dimenhydrinate (Dramamine) as vestibular depressants in squirrel monkeys which were subsequently subjected to caloric stimulation. The duration of nystagmus was measured visually, and although both agents appeared to be active vestibular depressants, no significant difference

×